Yesterday’s Solution; Tomorrow’s Problem
This article was originally published in RPM Report
Executive Summary
Two years ago, Sun Pharmaceuticals was a key part of FDA’s efforts in helping drug shortages; now FDA has banned imports from one of its plants.
You may also be interested in...
Sun’s Generic Doxil Clears FDA; Janssen Uses Alternative Manufacturing Process
FDA approval of the first generic version of Janssen’s Doxil to curtail drug’s shortage; agency also permits Janssen to use an alternative manufacturing process.
Doxil Shortage Solution: FDA Chooses Middle Ground, Allows Import Of Unapproved Version
FDA is allowing Sun Pharma Global FZE to import its unapproved liposomal version of doxorubicin, Lipodox, to alleviate a shortage, but has not yet given the drug full approval.
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.